Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study. This is an ASCO Meeting ...

In this Healio video, Alissa J. Cooper, MD, a thoracic oncologist at Dana-Farber Cancer Institute, discusses the TOP trial of osimertinib plus chemotherapy in high-risk patients with non-small cell ...

Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer worsening compared with Tagrisso alone. At the 2026 European Lung Cancer ...

Dysphagia in cancers of the lip, oral cavity, and pharynx patients: Impact on cachexia, hospitalization, and racial disparities on outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

Discover how TP53 mutations in adult leukaemia impact treatment outcomes and potential strategies for improved patient care.

The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...

A large CT imaging study identifies many clues which are the key risk factors linked to fast-growing lung cancer, supporting improved monitoring and follow-up strategies. Know more.

At the annual conference of the European Society of Human Genetics in Milan, biologist Dr. Edwige Kasper from the University Hospital of Rouen presented a case involving a sperm donor who unknowingly ...